"GeoArea_Code","GeoArea_Desc","ISO3CD","X","Y","GoalCode","GoalDesc","TargetCode","TargetDesc","IndicatorCode","IndicatorDesc","IndicatorTier","SeriesCode","SeriesDesc","SeriesRelease","Units_Code","Units_Desc","ReportingType_Code","ReportingType_Desc","Value_2000","Value_2001","Value_2002","Value_2003","Value_2004","Value_2005","Value_2006","Value_2007","Value_2008","Value_2009","Value_2010","Value_2011","Value_2012","Value_2013","Value_2014","Value_2015","Value_2016","Latest_Year","Latest_Value","Nature_Desc","Source"
"4","Afghanistan","AFG","66.02688198","33.83160199","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","24","33","36","41","50","58","58","63","64","63","66","68","67","64","62","65","65",2016.0,"65","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"8","Albania","ALB","20.06660928","41.13897007","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","97","97","98","97","97","98","97","98","99","98","99","99","99","99","98","99","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"10","Antarctica","ATA","21.47585697","-80.40897662","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"12","Algeria","DZA","2.678164227","28.15940032","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","86","89","86","87","86","88","95","95","93","95","95","95","95","95","95","95","91",2016.0,"91","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"16","American Samoa","ASM","-170.7187269","-14.30587306","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"20","Andorra","AND","1.576257417","42.54548611","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","98","96","97","99","99","98","93","96","99","99","99","99","99","96","97","97","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"24","Angola","AGO","17.57817062","-12.33724746","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","28","38","41","40","40","38","34","73","69","60","77","71","75","77","64","64","64",2016.0,"64","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"28","Antigua and Barbuda","ATG","-61.7999755","17.07761471","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","95","97","98","99","97","99","99","99","99","99","98","99","98","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"31","Azerbaijan","AZE","50.01064725","40.39229544","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","76","77","76","77","77","75","78","79","81","81","81","87","89","93","94","96","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"32","Argentina","ARG","-65.14563274","-35.19446255","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","83","83","93","96","98","98","91","91","93","94","94","91","91","94","94","94","92",2016.0,"92","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"36","Australia","AUS","134.3499412","-25.57717202","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","90","92","92","93","92","92","92","92","92","92","92","92","92","91","92","93","94",2016.0,"94","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"40","Austria","AUT","14.14172472","47.58704857","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","81","84","83","84","83","86","83","85","83","83","86","89","92","95","98","93","87",2016.0,"87","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"44","Bahamas","BHS","-78.05111663","24.69546597","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","99","94","92","93","93","95","95","93","96","99","98","98","97","96","95","94",2016.0,"94","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"48","Bahrain","BHR","50.5490754","26.04407747","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","97","99","98","97","98","98","98","97","97","98","99","99","99","99","98","98","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"50","Bangladesh","BGD","89.17660788","22.86961622","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","82","85","83","87","99","93","94","94","96","97","94","96","94","96","97","97","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"51","Armenia","ARM","44.93839317","40.29499741","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","93","94","94","94","91","90","87","88","89","93","94","95","95","95","93","94","94",2016.0,"94","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"52","Barbados","BRB","-59.5346489","13.13648273","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","93","84","87","89","93","92","84","93","85","93","86","91","87","91","94","97","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"56","Belgium","BEL","4.660976456","50.64104975","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","95","95","95","95","95","97","98","98","99","98","98","98","99","99","99","99","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"60","Bermuda","BMU","-64.78155012","32.27881922","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"64","Bhutan","BTN","90.45098484","27.39598568","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","92","88","86","95","89","95","95","95","96","93","91","95","97","97","99","99","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"68","Bolivia (Plurinational State of)","BOL","-64.66224284","-16.71273412","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","75","71","77","88","84","85","83","84","88","93","91","95","93","94","98","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"70","Bosnia and Herzegovina","BIH","17.78584332","44.16845548","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","85","91","80","87","84","93","87","95","91","90","89","88","92","89","86","82","78",2016.0,"78","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"72","Botswana","BWA","23.81380223","-22.18810073","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","97","97","97","96","96","96","96","96","96","96","95","95","95","95","95","95","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"74","Bouvet Island","BVT","3.410732868","-54.43295905","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"76","Brazil","BRA","-53.08432878","-10.77668561","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","98","98","99","99","99","99","99","99","99","99","99","99","95","97","93","96","86",2016.0,"86","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"84","Belize","BLZ","-88.70199554","17.19965901","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","91","96","89","96","97","96","98","96","94","97","96","95","98","95","95","94","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"86","British Indian Ocean Territory","IOT","72.38715553","-7.299281071","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"90","Solomon Islands","SLB","160.1584117","-9.622391719","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","86","84","78","84","90","89","99","90","89","92","90","99","99","94","88","98","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"92","British Virgin Islands","VGB","-64.63294223","18.42256578","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"96","Brunei Darussalam","BRN","114.6288563","4.49736984","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","97","94","92","92","94","97","99","98","99","95","97","99","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"100","Bulgaria","BGR","25.23763153","42.75731323","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","93","94","93","96","95","96","95","95","95","94","94","95","95","95","88","91","92",2016.0,"92","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"104","Myanmar","MMR","96.51752295","21.19332882","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","82","73","79","78","82","73","82","86","85","90","90","84","84","75","88","89","90",2016.0,"90","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"108","Burundi","BDI","29.89080992","-3.366387428","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","80","81","81","82","83","87","92","99","92","94","96","96","96","96","95","94","94",2016.0,"94","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"112","Belarus","BLR","28.04940161","53.54193075","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","99","99","50","99","99","99","95","97","96","98","98","98","98","97","99","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"116","Cambodia","KHM","104.922836","12.71163737","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","59","60","54","69","85","82","80","82","91","94","89","88","86","83","88","89","90",2016.0,"90","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"120","Cameroon","CMR","12.7419827","5.692387031","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","62","63","66","73","73","80","81","82","84","80","84","82","85","89","87","84","85",2016.0,"85","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"124","Canada","CAN","-101.6575058","57.72360191","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","89","89","88","91","91","93","95","94","92","91","89","87","95","91","91","91","91",2016.0,"91","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"132","Cabo Verde","CPV","-23.63544151","15.07791834","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","90","90","91","92","93","95","96","98","99","99","99","90","94","93","95","93","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"136","Cayman Islands","CYM","-81.16740559","19.32266656","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"140","Central African Republic","CAF","20.93559492","7.003720791","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","37","40","44","47","51","54","51","48","45","42","45","47","47","23","47","47","47",2016.0,"47","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"144","Sri Lanka","LKA","80.70489654","7.614693343","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","98","98","99","97","99","98","98","98","97","99","99","99","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"148","Chad","TCD","18.66618401","15.36279341","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","36","26","25","23","21","25","40","28","19","24","39","33","40","39","37","46","46",2016.0,"46","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"152","Chile","CHL","-71.23029019","-35.2652885","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","91","97","97","96","93","91","94","96","95","94","92","94","90","91","95","96","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"156","China","CHN","104.1403375","32.30955217","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","85","86","86","86","87","87","93","93","97","99","99","99","99","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"162","Christmas Island","CXR","105.6426067","-10.4882473","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"166","Cocos (Keeling) Islands","CCK","96.82633757","-12.18600682","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"170","Colombia","COL","-73.07446751","3.888209046","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","79","80","81","92","89","93","93","93","92","92","88","85","91","91","90","91","91",2016.0,"91","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"174","Comoros","COM","43.34234565","-11.66121732","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","70","70","89","80","76","68","69","75","81","83","74","83","86","87","87","91","91",2016.0,"91","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"175","Mayotte","MYT","45.14015057","-12.82217691","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"178","Congo","COG","15.22052612","-0.840544119","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","33","31","41","50","67","62","73","72","79","78","74","82","85","85","90","80","80",2016.0,"80","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"180","Democratic Republic of the Congo","COD","23.65496507","-2.877154732","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","40","30","38","41","54","60","62","70","65","72","60","74","75","74","80","81","79",2016.0,"79","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"184","Cook Islands","COK","-159.7711391","-21.22696458","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","92","90","97","96","99","99","99","99","99","82","99","93","98","98","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"188","Costa Rica","CRI","-84.19712782","9.970998683","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","88","91","94","88","90","91","89","89","90","86","88","85","91","95","91","92","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"191","Croatia","HRV","17.95874553","45.45172212","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","93","94","95","94","96","96","96","96","96","96","97","96","96","96","95","94","93",2016.0,"93","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"192","Cuba","CUB","-79.54460144","22.10030366","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","95","98","99","72","88","89","89","93","95","96","96","97","99","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"196","Cyprus","CYP","33.22285964","35.05659437","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","97","97","98","98","98","98","97","97","97","99","99","99","99","99","99","97","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"203","Czechia","CZE","15.33151382","49.73913871","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","98","98","98","97","98","97","98","99","99","99","99","99","99","98","97","97","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"204","Benin","BEN","2.339933594","9.65401646","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","78","76","75","73","72","70","74","82","75","79","76","75","80","77","78","82","82",2016.0,"82","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"208","Denmark","DNK","9.326571283","56.03829721","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","97","97","98","96","95","93","93","87","88","89","90","91","94","94","94","93","94",2016.0,"94","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"212","Dominica","DMA","-61.3493756","15.43391378","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","99","98","99","99","98","95","96","96","99","98","98","97","96","97","98","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"214","Dominican Republic","DOM","-70.49847576","18.89832088","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","78","72","82","79","79","87","89","85","82","82","88","84","85","83","91","85","87",2016.0,"87","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"218","Ecuador","ECU","-78.37005241","-1.447785891","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","87","89","88","87","88","92","96","96","96","94","91","88","87","87","83","78","83",2016.0,"83","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"222","El Salvador","SLV","-88.86862995","13.73603564","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","92","81","94","90","89","96","99","98","91","89","89","92","92","94","91","93",2016.0,"93","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"226","Equatorial Guinea","GNQ","10.46535826","1.565792376","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","34","35","36","37","38","39","40","41","42","43","44","41","24","3","20","16","19",2016.0,"19","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"231","Ethiopia","ETH","39.63505296","8.631223181","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","30","32","35","37","40","44","46","50","54","58","61","65","69","72","77","77","77",2016.0,"77","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"232","Eritrea","ERI","38.11074289","16.12894644","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","81","86","90","93","98","96","94","91","94","92","90","96","94","94","94","95","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"233","Estonia","EST","25.84093481","58.68487172","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","93","94","94","94","94","96","95","95","95","95","94","93","94","94","93","93","93",2016.0,"93","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"234","Faroe Islands","FRO","-7.122044325","62.21228119","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"238","Falkland Islands (Malvinas)","FLK","-58.75246778","-51.74562601","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"239","South Georgia and the South Sandwich Islands","SGS","-36.90662765","-54.20736749","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"242","Fiji","FJI","177.9660884","-17.83301566","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","90","91","93","94","95","96","98","99","99","99","99","99","99","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"246","Finland","FIN","23.308447","61.91586738","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","98","98","98","98","97","97","99","99","99","99","99","99","98","98","97","92",2016.0,"92","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"248","Åland Islands","ALA","19.80945969","60.1544901","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"250","France","FRA","2.457288129","46.62660861","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","97","97","97","97","98","98","99","98","98","98","99","99","99","99","98","98","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"254","French Guiana","GUF","-53.23619089","3.922673437","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"258","French Polynesia","PYF","-149.4052367","-17.67709294","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"260","French Southern Territories","ATF","69.64849091","-49.6068576","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"262","Djibouti","DJI","42.18274707","11.56004161","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","46","53","62","68","64","71","72","88","89","89","88","87","81","82","78","84","84",2016.0,"84","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"266","Gabon","GAB","11.78727747","-0.60687619","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","45","45","45","45","45","45","45","81","82","76","67","75","82","79","70","80","75",2016.0,"75","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"268","Georgia","GEO","43.3713615","42.04813028","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","80","87","84","75","78","82","88","98","92","88","92","94","92","93","91","94","92",2016.0,"92","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"270","Gambia","GMB","-15.39944785","13.45295927","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","80","87","87","87","87","95","95","95","96","98","97","96","98","97","96","97","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"275","State of Palestine","PSE","35.25694122","31.94347933","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","93","97","97","98","96","96","96","99","96","97","99","99","97","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"276","Germany","DEU","10.3806066","51.08862743","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","90","93","93","97","96","96","96","96","96","96","95","95","95","95","95","95","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"288","Ghana","GHA","-1.205623522","7.964825185","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","88","79","78","80","80","84","84","94","93","94","94","91","92","90","98","88","93",2016.0,"93","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"292","Gibraltar","GIB","-5.347561686","36.13895036","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"296","Kiribati","KIR","-157.5643005","1.768837732","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","90","85","77","70","62","79","86","94","82","86","91","99","94","95","75","78","81",2016.0,"81","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"300","Greece","GRC","22.58307827","39.47301873","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","89","91","92","94","95","96","98","99","99","99","99","99","99","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"304","Greenland","GRL","-41.39371316","74.75625681","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"308","Grenada","GRD","-61.68248568","12.11238395","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","97","96","98","97","83","99","91","96","99","99","97","95","97","97","97","92","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"312","Guadeloupe","GLP","-61.64762115","16.14416917","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"316","Guam","GUM","144.7029305","13.35485404","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"320","Guatemala","GTM","-91.2312746","15.00273719","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","81","77","82","84","87","87","89","85","95","92","94","88","96","85","73","74","80",2016.0,"80","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"324","Guinea","GIN","-11.28173419","11.00210343","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","46","50","53","57","60","59","57","63","60","57","64","63","62","63","51","54","57",2016.0,"57","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"328","Guyana","GUY","-58.97322037","4.788012784","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","88","85","91","90","91","93","93","94","93","98","95","93","97","98","98","95","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"332","Haiti","HTI","-72.33640958","18.40426539","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","41","45","48","53","55","60","60","63","63","65","66","68","67","68","48","60","58",2016.0,"58","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"334","Heard Island and McDonald Islands","HMD","73.52633626","-53.09106147","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"336","Holy See","VAT","12.45315803","41.90343751","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"340","Honduras","HND","-86.59974381","14.82243161","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","94","96","95","92","94","98","95","94","93","97","97","97","97","97","97","97","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"344","China, Hong Kong Special Administrative Region","HKG","114.0266445","22.41749934","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"348","Hungary","HUN","19.41221519","47.1651448","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","99","99","99","99","99","99","99","99","99","99","99","99","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"352","Iceland","ISL","-19.02116966","64.79134763","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","98","92","95","97","99","95","97","97","98","96","96","95","89","91","90","92","91",2016.0,"91","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"356","India","IND","79.3608464","22.34642074","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","58","59","59","61","63","65","65","64","70","74","79","82","82","83","85","87","88",2016.0,"88","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"360","Indonesia","IDN","113.9174","-0.994582204","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","75","76","70","71","71","72","72","73","77","78","81","81","83","85","78","78","79",2016.0,"79","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"364","Iran (Islamic Republic of)","IRN","54.19766348","32.74370885","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","96","99","99","99","95","98","99","99","99","99","99","99","98","99","98","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"368","Iraq","IRQ","43.76606267","33.05013795","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","80","78","77","75","74","65","59","57","69","78","74","79","69","68","64","58","63",2016.0,"63","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"372","Ireland","IRL","-7.121425272","53.25274054","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","86","84","83","86","89","90","91","92","93","94","94","95","95","96","96","95","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"376","Israel","ISR","34.62277992","31.06164552","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","93","92","90","93","95","93","95","95","94","96","95","94","94","96","95","95","94",2016.0,"94","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"380","Italy","ITA","12.57022427","42.79917282","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","87","93","93","96","94","95","96","97","96","96","96","96","97","96","95","93","93",2016.0,"93","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"384","Côte d'Ivoire","CIV","-5.552690016","7.62211586","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","65","66","64","61","67","76","77","76","74","81","85","62","82","80","76","83","85",2016.0,"85","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"388","Jamaica","JAM","-77.31068409","18.15616857","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","93","99","99","96","98","99","95","92","91","90","94","92","96","93","92","91","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"392","Japan","JPN","139.2716103","36.6554539","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","85","95","96","97","99","98","98","98","98","97","97","97","97","96","96","96","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"398","Kazakhstan","KAZ","66.65359159","48.01963494","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","97","95","95","99","82","98","99","93","99","98","99","99","99","98","95","98","82",2016.0,"82","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"400","Jordan","JOR","37.13024774","30.65365973","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","91","99","95","97","95","95","98","98","97","98","98","98","98","98","98","99","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"404","Kenya","KEN","37.86096816","0.534797278","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","82","80","84","73","73","76","80","81","88","88","90","96","94","87","92","89","89",2016.0,"89","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"408","Democratic People's Republic of Korea","PRK","127.1803633","40.1462645","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","56","62","64","68","72","79","89","92","92","93","93","94","96","93","93","96","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"410","Republic of Korea","KOR","127.8610254","36.45201023","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","97","97","97","97","88","96","98","91","94","94","94","99","99","99","99","98","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"414","Kuwait","KWT","47.49305029","29.53949468","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","98","99","99","99","98","99","99","99","99","99","98","99","98","99","95","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"417","Kyrgyzstan","KGZ","74.52324839","41.46204516","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","99","98","98","99","98","92","94","95","95","96","96","96","97","96","97","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"418","Lao People's Democratic Republic","LAO","101.9901968","20.27482773","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","51","52","53","49","45","49","57","50","61","67","74","78","79","87","88","89","82",2016.0,"82","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"422","Lebanon","LBN","35.89391711","33.92152458","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","83","80","77","74","75","77","78","80","81","81","81","81","81","81","81","81","81",2016.0,"81","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"426","Lesotho","LSO","28.25362195","-29.58041814","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","83","78","84","90","90","89","89","88","88","91","93","96","95","93","93","93","93",2016.0,"93","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"428","Latvia","LVA","26.42461876","56.64196636","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","96","97","97","98","99","99","96","94","94","94","92","92","91","94","92","95","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"430","Liberia","LBR","-9.311879038","6.448381009","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","46","42","39","35","31","60","60","65","75","81","70","77","80","76","50","52","79",2016.0,"79","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"434","Libya","LBY","18.0295985","27.04042819","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","94","94","93","95","97","98","98","98","98","98","98","98","98","96","94","97","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"438","Liechtenstein","LIE","9.552985019","47.14167005","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"440","Lithuania","LTU","23.90517807","55.33680309","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","94","95","95","94","94","94","94","95","96","98","95","92","93","93","93","93","94",2016.0,"94","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"442","Luxembourg","LUX","6.092656563","49.77679538","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","99","99","98","99","99","99","99","99","99","99","99","99","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"446","China, Macao Special Administrative Region","MAC","113.5665388","22.1237259","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"450","Madagascar","MDG","46.6982339","-19.38514785","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","57","60","62","66","78","85","85","84","77","77","70","73","70","74","73","69","77",2016.0,"77","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"454","Malawi","MWI","33.4884625","-13.40819859","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","75","90","64","84","89","93","99","87","91","93","93","97","96","89","91","88","84",2016.0,"84","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"458","Malaysia","MYS","116.8346314","5.452415309","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","98","96","94","96","95","96","95","97","97","97","96","96","97","97","97","99","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"462","Maldives","MDV","73.09672546","-0.614385021","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","98","98","98","98","96","98","98","98","98","98","96","96","99","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"466","Mali","MLI","-3.522016039","17.35311254","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","43","49","61","63","69","77","78","74","74","73","73","66","66","69","73","64","68",2016.0,"68","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"470","Malta","MLT","14.44617519","35.89194275","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","94","95","95","94","89","92","85","74","72","73","76","96","99","99","99","97","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"474","Martinique","MTQ","-60.91544135","14.56086108","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"478","Mauritania","MRT","-10.33187259","20.26089546","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","51","75","89","76","70","71","68","75","74","64","64","75","80","80","84","73","73",2016.0,"73","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"480","Mauritius","MUS","57.568022","-20.28581998","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","88","92","88","99","98","97","97","97","99","99","99","98","98","98","97","97","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"484","Mexico","MEX","-102.5148166","23.93378032","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","97","97","97","98","98","98","98","98","96","95","95","97","99","83","87","87","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"492","Monaco","MCO","7.424214814","43.73532918","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","99","99","99","99","99","99","99","99","99","99","99","99","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"496","Mongolia","MNG","103.0728057","46.83892054","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","94","95","98","98","99","99","99","95","96","95","96","99","99","98","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"498","Republic of Moldova","MDA","28.4650624","47.20236795","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","95","97","97","98","98","98","97","92","90","85","90","93","92","90","90","87","89",2016.0,"89","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"499","Montenegro","MNE","19.25214024","42.78717043","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","90","92","95","92","94","95","94","94","91","89","89",2016.0,"89","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"500","Montserrat","MSR","-62.19261223","16.73558313","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"504","Morocco","MAR","-6.281942841","31.8440131","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","95","96","94","91","97","98","97","95","99","99","99","99","99","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"508","Mozambique","MOZ","38.18479941","-14.27963886","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","70","73","76","85","83","80","78","75","75","74","74","76","76","78","79","80","80",2016.0,"80","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"512","Oman","OMN","57.87743482","21.98805614","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","99","99","99","99","99","98","99","99","98","99","99","98","98","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"516","Namibia","NAM","17.21907885","-22.13817068","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","79","78","77","79","81","86","86","86","83","83","83","82","84","89","88","92","92",2016.0,"92","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"520","Nauru","NRU","166.92313","-0.528742623","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","44","95","80","80","80","80","72","99","99","99","99","99","79","87","95","91","91",2016.0,"91","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"524","Nepal","NPL","83.94678863","28.25866332","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","74","72","72","78","80","75","89","82","82","89","82","92","90","92","92","91","87",2016.0,"87","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"528","Netherlands","NLD","5.331480568","51.86728884","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","97","97","97","98","98","96","96","97","97","97","97","97","97","97","96","95","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"530","Netherlands Antilles","ANT","-68.30676179","12.22720635","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"531","Curaçao","CUW","-68.95033464","12.15058042","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"533","Aruba","ABW","-69.97050586","12.50878756","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"534","Sint Maarten (Dutch part)","SXM","-63.06198692","18.03926508","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"540","New Caledonia","NCL","165.5067368","-21.41742531","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"548","Vanuatu","VUT","167.0679779","-15.34445547","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","71","70","70","69","69","68","68","67","67","66","65","65","64","64","64","64","64",2016.0,"64","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"554","New Zealand","NZL","170.4755673","-43.98721568","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","90","90","90","90","89","89","89","88","89","92","93","95","93","92","93","92","92",2016.0,"92","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"558","Nicaragua","NIC","-85.03060315","12.84210839","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","83","87","85","86","79","86","88","93","97","98","98","98","98","98","98","98","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"562","Niger","NER","9.400167877","17.42143036","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","34","36","39","41","43","45","51","57","67","71","70","75","71","67","68","65","67",2016.0,"67","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"566","Nigeria","NGA","8.097363256","9.585789025","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","29","27","25","29","33","36","40","42","53","63","54","48","42","46","49","49","49",2016.0,"49","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"570","Niue","NIU","-169.8601693","-19.05000475","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","99","99","94","99","84","99","98","99","99","99","98","98","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"574","Norfolk Island","NFK","167.9515548","-29.03230018","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"578","Norway","NOR","11.47846389","61.34311134","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","90","91","93","92","92","91","94","93","94","94","93","94","95","94","93","95","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"580","Northern Mariana Islands","MNP","145.7582114","15.19099517","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"581","US Minor Outlying Islands","UMI","-162.4343752","5.874443968","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"583","Micronesia (Federated States of)","FSM","158.225216","6.880670092","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","85","75","84","92","78","94","67","79","85","91","85","84","81","81","77","72","69",2016.0,"69","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"583","Micronesia, Federated States of","FSM","158.225216","6.880670092","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"584","Marshall Islands","MHL","171.0839119","7.110213497","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","39","48","80","68","64","77","74","93","95","96","94","87","80","79","78","85","71",2016.0,"71","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"585","Palau","PLW","134.5733878","7.502307591","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","96","98","99","99","98","98","98","94","92","49","69","84","89","99","95","90","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"586","Pakistan","PAK","68.80479684","29.36491634","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","62","65","68","67","65","77","78","75","62","71","82","74","72","72","72","72","72",2016.0,"72","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"591","Panama","PAN","-81.26616623","8.450965746","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","98","99","99","98","95","92","88","85","86","85","94","87","85","80","80","73","73",2016.0,"73","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"598","Papua New Guinea","PNG","145.8587761","-6.756057077","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","59","55","61","68","62","72","72","71","63","73","67","72","74","79","73","73","72",2016.0,"72","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"600","Paraguay","PRY","-60.54854225","-21.70216237","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","86","89","87","86","92","96","98","95","89","85","89","89","87","86","87","93","93",2016.0,"93","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"604","Peru","PER","-71.82093277","-13.58939705","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","98","90","95","94","86","77","94","93","93","93","93","91","95","88","88","90","89",2016.0,"89","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"608","Philippines","PHL","120.8601418","14.16591706","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","78","79","79","84","88","89","88","87","91","87","79","87","88","89","67","60","86",2016.0,"86","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"612","Pitcairn","PCN","-128.3225873","-24.37538456","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"616","Poland","POL","19.40660158","52.1226733","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","98","98","99","99","99","99","99","99","99","99","99","99","99","99","98","98","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"620","Portugal","PRT","-7.961599811","39.68509315","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","96","97","98","99","95","93","97","97","97","96","98","97","98","98","98","98","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"624","Guinea-Bissau","GNB","-14.40182514","12.11760394","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","49","53","57","60","64","68","71","74","77","80","83","86","87","87","87","87","87",2016.0,"87","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"626","Timor-Leste","TLS","125.9451052","-8.797497247","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","54","55","57","55","63","70","79","72","72","67","83","82","77","76","85",2016.0,"85","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"630","Puerto Rico","PRI","-66.47591017","18.22753799","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"634","Qatar","QAT","51.19152467","25.28355379","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","80","93","96","92","96","97","96","94","97","99","97","93","92","97","89","99","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"638","Réunion","REU","55.53171398","-21.13183266","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"642","Romania","ROU","24.98481009","45.83893563","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","99","98","97","97","97","97","96","96","95","94","89","91","92","94","89","89",2016.0,"89","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"643","Russian Federation","RUS","99.01404926","61.61899849","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","96","96","97","96","97","98","98","98","98","98","97","97","97","97","97","97","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"646","Rwanda","RWA","29.92310194","-1.999842114","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","90","77","88","96","89","95","99","97","97","97","97","97","98","98","98","98","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"652","Saint Barthélemy","BLM","-62.83173536","17.89513362","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"654","Saint Helena","SHN","-5.705752501","-15.96503946","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"659","Saint Kitts and Nevis","KNA","-62.76628613","17.33994219","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","98","99","96","98","95","99","99","99","98","97","95","97","97","96","97","93","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"660","Anguilla","AIA","-63.05651612","18.21525315","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"662","Saint Lucia","LCA","-60.96529553","13.89405601","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","70","99","74","90","91","95","85","99","96","95","97","99","98","99","99","99","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"663","Saint Martin (French Part)","MAF","-63.04505461","18.0882685","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"666","Saint Pierre and Miquelon","SPM","-56.33682442","46.85812735","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"670","Saint Vincent and the Grenadines","VCT","-61.19024321","13.24627968","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","98","99","99","99","99","99","99","99","99","99","99","96","96","97","98","98","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"674","San Marino","SMR","12.46329038","43.93841766","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","96","96","96","96","98","95","95","92","87","92","79","86","96","69","80","76","66",2016.0,"66","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"678","Sao Tome and Principe","STP","6.609772265","0.241554875","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","82","92","92","94","96","97","97","97","99","98","98","96","96","97","95","96","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"682","Saudi Arabia","SAU","44.54763347","24.12594211","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","95","97","95","95","96","96","96","96","98","98","98","98","98","98","98","98","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"686","Senegal","SEN","-14.46636926","14.35920905","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","52","52","60","73","87","84","89","94","88","86","89","92","91","92","89","89","93",2016.0,"93","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"688","Serbia","SRB","20.805876","44.03145697","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","95","93","95","89","88","98","92","94","95","95","91","94","91","95","93","95","92",2016.0,"92","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"690","Seychelles","SYC","55.46561591","-4.678053059","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","98","96","99","99","99","99","99","99","99","99","99","99","98","98","99","97","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"694","Sierra Leone","SLE","-11.78306584","8.568604164","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","44","38","53","73","65","65","64","64","77","84","86","89","91","92","83","86","84",2016.0,"84","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"702","Singapore","SGP","103.8107883","1.361009155","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","98","96","94","96","95","96","95","97","97","97","96","96","97","97","96","96","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"703","Slovakia","SVK","19.48495604","48.70741446","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","99","99","99","99","99","99","99","99","99","99","99","99","98","97","96","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"704","Viet Nam","VNM","105.802499","10.09643079","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","96","96","75","99","96","95","94","92","93","96","93","95","97","59","95","97","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"705","Slovenia","SVN","14.82209486","46.11958061","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","91","92","93","95","94","95","97","97","97","96","96","96","96","95","95","95","94",2016.0,"94","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"706","Somalia","SOM","46.20367477","4.406485729","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","33","33","40","40","30","35","26","40","31","42","45","41","42","42","42","42","42",2016.0,"42","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"710","South Africa","ZAF","24.67184355","-29.99957544","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","73","71","70","69","74","79","82","82","79","76","72","69","65","73","77","75","66",2016.0,"66","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"716","Zimbabwe","ZWE","29.86909584","-19.00075492","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","78","75","71","68","65","68","70","73","75","73","89","93","95","95","91","87","90",2016.0,"90","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"724","Spain","ESP","-3.554078296","40.39211472","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","95","96","98","98","97","96","98","96","97","96","97","97","97","96","97","97","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"728","South Sudan","SSD","30.32618773","7.290839152","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","61","59","45","39","31","26",2016.0,"26","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"732","Western Sahara","ESH","-13.13515523","24.66265342","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"736","Sudan","SDN","29.95650159","16.02643066","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"740","Suriname","SUR","-55.90626394","4.132603197","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","71","68","73","75","85","83","84","84","85","87","96","86","84","86","85","89","91",2016.0,"91","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"744","Svalbard and Jan Mayen Islands","SJM","13.38071013","78.82894131","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"748","Eswatini","SWZ","31.50149288","-26.56471011","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","84","84","85","85","86","86","87","87","88","88","89","91","95","98","98","90","90",2016.0,"90","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"752","Sweden","SWE","14.3775338","60.60103109","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","99","99","99","99","98","98","98","98","98","98","98","98","98","98","98","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"756","Switzerland","CHE","8.223158","46.96617097","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","93","93","93","93","93","94","94","94","95","95","95","96","96","96","96","97","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"760","Syrian Arab Republic","SYR","38.50466565","35.01676176","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","84","82","84","83","81","80","80","80","79","80","80","72","45","41","43","41","42",2016.0,"42","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"762","Tajikistan","TJK","69.294998","38.43069666","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","83","85","85","85","86","84","83","86","86","93","93","96","94","96","97","96","96",2016.0,"96","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"764","Thailand","THA","101.0202951","15.13089239","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","97","96","96","98","98","98","98","98","99","99","99","99","99","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"768","Togo","TGO","0.97835765","8.532096072","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","64","50","59","72","71","82","84","82","81","78","83","85","84","84","87","88","89",2016.0,"89","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"772","Tokelau","TKL","-171.8154473","-9.214545558","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"776","Tonga","TON","-175.1959991","-21.19511329","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","91","89","84","90","90","89","88","87","86","84","82","82","77","82","80","78","78",2016.0,"78","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"780","Trinidad and Tobago","TTO","-61.29389504","10.41877263","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","90","91","96","91","94","95","92","88","90","90","90","90","92","92","92","96","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"784","United Arab Emirates","ARE","53.98279159","23.43322219","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","94","94","94","94","94","94","92","92","92","93","94","95","96","98","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"788","Tunisia","TUN","9.572737411","34.11439971","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","97","98","96","95","97","98","99","98","99","99","98","98","97","98","98","98","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"792","Turkey","TUR","35.42890329","38.9899684","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","85","88","78","68","85","90","90","96","96","96","97","97","97","98","96","97","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"795","Turkmenistan","TKM","58.9787665","40.0912346","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","97","95","98","83","97","99","98","98","96","96","96","97","97","98","98","99","98",2016.0,"98","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"796","Turks and Caicos Islands","TCA","-71.745121","21.80780585","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"798","Tuvalu","TUV","178.6679611","-7.460048071","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","82","96","98","93","98","93","97","97","99","88","89","96","97","90","89","96","94",2016.0,"94","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"800","Uganda","UGA","32.39100438","1.279557331","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","52","55","57","59","62","64","64","73","71","79","80","82","78","78","78","78","78",2016.0,"78","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"804","Ukraine","UKR","31.40270802","49.00735945","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","99","99","97","99","96","98","98","90","71","52","50","76","76","23","23","19",2016.0,"19","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"807","Macedonia, Republic of","MKD","21.7007909","41.60048068","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"807","The former Yugoslav Republic of Macedonia","MKD","21.7007909","41.60048068","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","95","91","96","96","94","97","93","95","95","96","95","96","95","98","95","91","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"818","Egypt","EGY","29.77468534","26.57438204","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","98","99","97","98","97","98","98","98","97","97","97","96","93","97","94","93","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"826","United Kingdom of Great Britain and Northern Ireland","GBR","-2.23830539","53.27691757","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","91","91","91","91","92","91","92","92","92","93","94","95","95","95","95","96","94",2016.0,"94","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"826","United Kingdom","GBR","-2.23830539","53.27691757","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"831","Guernsey","GGY","-2.200712402","49.71561166","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"832","Jersey","JEY","-2.136773508","49.22353354","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"833","Isle of Man","IMN","-4.538190305","54.22880901","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"834","Tanzania, United Republic of","TZA","34.80521182","-6.265332606","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"834","United Republic of Tanzania","TZA","34.80521182","-6.265332606","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","79","87","89","95","95","90","90","83","86","85","91","90","92","91","97","98","97",2016.0,"97","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"840","United States of America","USA","-99.13830311","39.5277871","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","94","94","94","96","96","96","96","96","96","95","95","96","94","94","95","95","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"850","United States Virgin Islands","VIR","-64.76960113","17.73297693","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"854","Burkina Faso","BFA","-1.742843829","12.27491081","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","45","62","69","79","79","82","86","89","93","92","91","91","90","88","91","91","91",2016.0,"91","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"858","Uruguay","URY","-56.01387025","-32.8002838","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","90","94","95","91","94","96","95","94","94","95","95","95","95","94","95","95","95",2016.0,"95","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"860","Uzbekistan","UZB","63.11944558","41.77560518","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","99","99","99","98","99","99","96","96","98","98","99","99","99","99","99","99","99",2016.0,"99","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"862","Venezuela (Bolivarian Republic of)","VEN","-66.15642084","7.121324748","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","77","70","65","68","86","87","71","62","50","84","78","78","81","82","78","87","84",2016.0,"84","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"876","Wallis and Futuna Islands","WLF","-176.2034788","-13.28471201","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","","","","","","","","","","","","","","","","","","","","",""
"882","Samoa","WSM","-172.4430749","-13.61541469","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","95","85","86","83","55","49","39","53","26","49","62","65","64","67","63","66","62",2016.0,"62","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"887","Yemen","YEM","45.22389143","15.22242099","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","74","73","65","61","72","79","78","79","78","76","76","69","67","73","73","69","71",2016.0,"71","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
"894","Zambia","ZMB","27.850329","-14.59701056","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_DTP3","Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3) (%)","2019.Q1.G.01","PERCENT","Percentage","G","Global","85","85","84","83","83","82","81","80","87","94","83","81","78","79","86","90","91",2016.0,"91","Estimated data","WHO/UNICEF coverage estimates 2016 revision, July 2017"
